Skip to Content

Methenamine / sodium biphosphate Disease Interactions

There are 8 disease interactions with methenamine / sodium biphosphate:

Major

Laxatives (applies to methenamine/sodium biphosphate) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (applies to methenamine/sodium biphosphate) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
View all 5 references
Major

Methenamine (applies to methenamine/sodium biphosphate) crystalluria

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction, Dehydration

The use of methenamine salts (i.e. methenamine hippurate or mandelate), but not the base, is contraindicated in patients with severe renal impairment or dehydration. Methenamine is excreted by the kidney and concentrated in the urine. In patients with low urinary output, the salts can precipitate and cause crystalluria.

References

  1. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  2. Klinge E, Mannisto P, Mantyla R, Lamminsivu U, Ottoila P "Pharmacokinetics of methenamine in healthy volunteers." J Antimicrob Chemother 9 (1982): 209-16
  3. Australian Drug Evaluation Committee "Adverse effects of drugs commonly used in the treatment of urinary tract infection." Med J Aust 1 (1972): 435-8
  4. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  5. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  6. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
View all 6 references
Major

Methenamine (applies to methenamine/sodium biphosphate) gout

Major Potential Hazard, Moderate plausibility.

Methenamine mandelate (salts), should be avoided in patients with gout as it may precipitate urate crystals in their urine. A similar situation may arise in patients with a predisposition to the formation of uric acid stones.

Major

Methenamine (applies to methenamine/sodium biphosphate) liver disease

Major Potential Hazard, High plausibility.

The use of methenamine and its salts (i.e. methenamine hippurate or mandelate) is contraindicated in patients with severe hepatic impairment. Methenamine is hydrolyzed to ammonia and formaldehyde in the urine under acidic conditions. Patients with liver disease may already have elevated ammonia levels, which can cause or exacerbate hepatic encephalopathy. Methenamine hippurate has also been associated with isolated cases of transient elevations in serum transaminases. The manufacturer recommends periodic liver function tests during therapy, particularly in patients with preexisting liver dysfunction.

References

  1. Strom J, Jun H "Kinetics of hydrolysis of methenamine." Pharm Bull 23 (1975): 651
  2. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
  3. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  4. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  5. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
View all 5 references
Major

Phosphates (applies to methenamine/sodium biphosphate) hypocalcemia

Major Potential Hazard, High plausibility. Applicable conditions: Pancreatitis

The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.

References

  1. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
  2. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
Major

Phosphates (applies to methenamine/sodium biphosphate) phosphate imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Hypoparathyroidism, Renal Dysfunction

Therapy with phosphates should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Elevated serum concentrations of phosphate and calcium can exceed the solubility level and result in calcium-phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
  2. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
Major

Sodium phosphate (applies to methenamine/sodium biphosphate) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Dehydration, Congestive Heart Failure, Phosphate Imbalance, Gastrointestinal Obstruction, Inflammatory Bowel Disease

The use of sodium phosphates is contraindicated in patients with congenital megacolon, intestinal obstruction, imperforate anus, active inflammatory disease or congestive heart failure. Serious, potentially life-threatening electrolyte imbalance such as hypocalcemia and hyperphosphatemia can result with prolonged or excessive use of phosphate laxatives. Hypernatremia and dehydration can occur due to improper dilution of hypertonic saline laxatives. Therapy with sodium phosphates should be administered cautiously and frequency of administration limited in patients with renal dysfunction, colostomy, cardiac dysfunction, or electrolyte imbalance. Clinical monitoring of electrolyte concentrations is recommended.

References

  1. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
  2. "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical, Abbott Park, IL.

Methenamine / sodium biphosphate drug interactions

There are 409 drug interactions with methenamine / sodium biphosphate

Methenamine / sodium biphosphate alcohol/food interactions

There is 1 alcohol/food interaction with methenamine / sodium biphosphate

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.